Document is current
Any future updates will be listed below
-
Authors
Agez, Morgane
Schultz, Patrick
Medina, Igor https://orcid.org/0000-0001-6839-5414
Baker, David J.
Burnham, Matthew P.
Cardarelli, Ross A. https://orcid.org/0000-0002-3692-6708
Conway, Leslie C.
Garnier, Kelly
Geschwindner, Stefan
Gunnarsson, Anders
McCall, Eileen J.
Frechard, Alexandre
Audebert, Stéphane https://orcid.org/0000-0002-9409-2588
Deeb, Tarek Z.
Moss, Stephen J.
Brandon, Nicholas J.
Wang, Qi
Dekker, Niek
Jawhari, Anass
- License Information
-
More Information
Article History
Received: 14 June 2017
Accepted: 27 October 2017
First Online: 28 November 2017
Competing Interests
: The authors MA, KG and AJ are employees of CALIXAR that have patents applications that covers CALX R1-6 described in this manuscript. A part from that, all authors have no competing interests as defined by Nature Publishing Group, or other interests that might be perceived to influence the results and/or discussion reported in this paper. DB, MB, SG, AG, EM, NB, QW, and ND are full–time employees and shareholders of AstraZeneca. SM serves as a consultant for SAGE therapeutics and AstraZeneca, relationships that are regulated by Tufts University.
